Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series

S. Ruf, H. Hebart, LL. Hjalgrim, E. Kabickova, P. Lang, D. Steinbach, GC. Schwabe, W. Woessmann,

. 2018 ; 65 (6) : e27003. [pub] 20180307

Jazyk angličtina Země Spojené státy americké

Typ dokumentu kazuistiky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028531

Vinblastine and targeted therapies induce remissions in patients with relapsed or progressive anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). Central nervous system (CNS) prophylaxis often is not included during re-induction in CNS-negative relapse patients. We report on five patients with progressive or early relapsed ALK-positive ALCL who developed CNS progression during re-induction with vinblastine, crizotinib, or brentuximab vedotin given for bridging to allogeneic blood stem cell transplantation. These observations suggest that CNS prophylaxis should be considered in ALCL patients suffering progression during initial therapy who receive re-induction using agents with limited CNS penetration.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028531
003      
CZ-PrNML
005      
20190815112052.0
007      
ta
008      
190813s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/pbc.27003 $2 doi
035    __
$a (PubMed)29512859
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ruf, Stephanie $u Department of Pediatric Hematology and Oncology, Justus Liebig University Giessen, Giessen, Germany.
245    10
$a CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series / $c S. Ruf, H. Hebart, LL. Hjalgrim, E. Kabickova, P. Lang, D. Steinbach, GC. Schwabe, W. Woessmann,
520    9_
$a Vinblastine and targeted therapies induce remissions in patients with relapsed or progressive anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). Central nervous system (CNS) prophylaxis often is not included during re-induction in CNS-negative relapse patients. We report on five patients with progressive or early relapsed ALK-positive ALCL who developed CNS progression during re-induction with vinblastine, crizotinib, or brentuximab vedotin given for bridging to allogeneic blood stem cell transplantation. These observations suggest that CNS prophylaxis should be considered in ALCL patients suffering progression during initial therapy who receive re-induction using agents with limited CNS penetration.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a anaplastická lymfomová kináza $x metabolismus $7 D000077548
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $7 D000971
650    _2
$a nemoci centrálního nervového systému $x chemicky indukované $x patologie $7 D002493
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a anaplastický velkobuněčný lymfom $x farmakoterapie $x patologie $7 D017728
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a cílená molekulární terapie $x škodlivé účinky $7 D058990
650    _2
$a lokální recidiva nádoru $x farmakoterapie $x patologie $7 D009364
650    _2
$a prognóza $7 D011379
650    _2
$a míra přežití $7 D015996
650    _2
$a vinblastin $x škodlivé účinky $7 D014747
650    _2
$a mladý dospělý $7 D055815
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hebart, Holger $u Department of Internal Medicine, Stauferklinikum Schwaebisch Gmuend, Mutlangen, Germany.
700    1_
$a Hjalgrim, Lisa Lyngsie $u The Child and Youth Clinic, Department of Pediatric Hematology and Oncology, University Hospital Copenhagen, Copenhagen, Denmark.
700    1_
$a Kabickova, Edita $u Department of Pediatric Hematology and Oncology, Charles University and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Lang, Peter $u Department of Pediatric Hematology and Oncology, Eberhard Karls University Tuebingen, Tuebingen, Germany.
700    1_
$a Steinbach, Daniel $u Department of Pediatric Hematology and Oncology, University Hospital Ulm, Ulm, Germany.
700    1_
$a Schwabe, Georg C $u Children's Hospital Cottbus, Cottbus, Germany.
700    1_
$a Woessmann, Wilhelm $u Department of Pediatric Hematology and Oncology, Justus Liebig University Giessen, Giessen, Germany.
773    0_
$w MED00181047 $t Pediatric blood & cancer $x 1545-5017 $g Roč. 65, č. 6 (2018), s. e27003
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29512859 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190815112320 $b ABA008
999    __
$a ok $b bmc $g 1433680 $s 1066991
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 65 $c 6 $d e27003 $e 20180307 $i 1545-5017 $m Pediatric blood & cancer $n Pediatr Blood Cancer $x MED00181047
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Možnosti archivace